In the past 12‑18 months, the Disposable Sphincterotome market has experienced a cascade of strategic moves that are reshaping the competitive landscape. In March 2024, MedTech leader Olympus partnered with Swiss‑based EndoInnovate to co‑develop a hydrophilic‑coated, ultra‑low‑profile sphincterotome designed for complex biliary interventions, accelerating rollout across Europe and Asia. Meanwhile, Boston Scientific completed its acquisition of micro‑device maker VascularTech in July 2024, adding a proprietary polymer extrusion platform that promises a 30 % reduction in manufacturing waste. The same month, Johnson & Johnson launched the EcoSphincter line, featuring a biodegradable handle and a built‑in radiopaque marker, which received CE‑Mark approval in September. Regulatory momentum continued as the U.S. FDA introduced revised guidance on single‑use endoscopic accessories in November 2024, tightening sterility validation but also opening pathways for expedited 510(k) submissions. Finally, a $45 million Series C round led by HealthVentures enabled a start‑up, ClearPath Devices, to expand its pilot facility in Singapore, targeting the fast‑growing APAC demand for cost‑effective disposable tools. These developments collectively illustrate the accelerating pace of innovation and consolidation within the Disposable Sphincterotome industry trends.
